ArticleInternational journal of radiation oncology, biology, physics2016
Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer.
Article in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Technical Considerations on Proton Therapy in NRG's Multi-Institutional Clinical Trials.International journal of radiation oncology, biology, physics · 2026Guideline
- Offline Plan Adaptation in Robustly Optimized CBCT-Guided Pencil Beam Scanning Proton Beam Therapy: Lessons From a Real-World Cohort.Advances in radiation oncology · 2026Article
- Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities.Tomography (Ann Arbor, Mich.) · 2026Review
- Noisy probing dose facilitated dose prediction for pencil beam scanning proton therapy: Physics enhances generalizability.Medical physics · 2026Article
- Proton stereotactic body radiotherapy for early-stage non-small cell lung cancer: Influence of case-specific characteristics on dosimetric robustness.Journal of applied clinical medical physics · 2026Article
- Quantifying interplay effects in lung cancer IMPT: a comprehensive analysis of treatment planning parameter sensitivity.BMC cancer · 2025Article
- Impact of four-dimensional computed tomography phase number on target coverage of four-dimensional robustly optimized lung stereotactic body radiotherapy.Scientific reports · 2025Article
- Assessment of intra-fractional and inter-fractional motion in esophageal cancer treated with intensity-modulated proton therapy.BMC cancer · 2025Article
- Scenario-free robust optimization algorithm for IMRT and IMPT treatment planning.Medical physics · 2025Article
- Enabling clinical use of linear energy transfer in proton therapy for head and neck cancer - A review of implications for treatment planning and adverse events study.Visualized cancer medicine · 2025Article
- Time structures of proton pencil beam scanning delivery on a microsecond scale measured with a pixelated semiconductor detector Timepix3.Journal of applied clinical medical physics · 2024Article
- NRG Oncology and Particle Therapy Co-Operative Group Patterns of Practice Survey and Consensus Recommendations on Pencil-Beam Scanning Proton Stereotactic Body Radiation Therapy and Hypofractionated Radiation Therapy for Thoracic Malignancies.International journal of radiation oncology, biology, physics · 2024Review
- Clinical Viability of an Active Spot Scanning Beam Delivery System With a Newly Developed Carbon-Ion Treatment Planning System.Advances in radiation oncology · 2024Article
- Article
- Modelling small block aperture in an in-house developed GPU-accelerated Monte Carlo-based dose engine for pencil beam scanning proton therapy.Physics in medicine and biology · 2024Article
- Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy.Frontiers in oncology · 2024Article
- Deep-learning based fast and accurate 3D CT deformable image registration in lung cancer.Medical physics · 2023Article
- Artificial general intelligence for radiation oncology.Meta-radiology · 2023Article
- Comparison of 3D and 4D robustly optimized proton treatment plans for non-small cell lung cancer patients with tumour motion amplitudes larger than 5 mm.Physics and imaging in radiation oncology · 2023Article
- Emerging technologies for cancer therapy using accelerated particles.Progress in particle and nuclear physics · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
Abstract
purposeThe purpose of this study was to compare the impact of uncertainties and interplay on 3-dimensional (3D) and 4D robustly optimized intensity modulated proton therapy (IMPT) plans for lung cancer in an exploratory methodology study. METHODS AND MATERIALS: IMPT plans were created for 11 nonrandomly selected non-small cell lung cancer (NSCLC) cases: 3D robustly optimized plans on average CTs with internal gross tumor volume density overridden to irradiate internal target volume, and 4D robustly optimized plans on 4D computed tomography (CT) to irradiate clinical target volume (CTV). Regular fractionation (66 Gy [relative biological effectiveness; RBE] in 33 fractions) was considered. In 4D optimization, the CTV of individual phases received nonuniform doses to achieve a uniform cumulative dose. The root-mean-square dose-volume histograms (RVH) measured the sensitivity of the dose to uncertainties, and the areas under the RVH curve (AUCs) were used to evaluate plan robustness. Dose evaluation software modeled time-dependent spot delivery to incorporate interplay effect with randomized starting phases of each field per fraction. Dose-volume histogram (DVH) indices comparing CTV coverage, homogeneity, and normal tissue sparing were evaluated using Wilcoxon signed rank test.
results4D robust optimization plans led to smaller AUC for CTV (14.26 vs 18.61, respectively; P=.001), better CTV coverage (Gy [RBE]) (D95% CTV: 60.6 vs 55.2, respectively; P=.001), and better CTV homogeneity (D5%-D95% CTV: 10.3 vs 17.7, respectively; P=.002) in the face of uncertainties. With interplay effect considered, 4D robust optimization produced plans with better target coverage (D95% CTV: 64.5 vs 63.8, respectively; P=.0068), comparable target homogeneity, and comparable normal tissue protection. The benefits from 4D robust optimization were most obvious for the 2 typical stage III lung cancer patients.
conclusionsOur exploratory methodology study showed that, compared to 3D robust optimization, 4D robust optimization produced significantly more robust and interplay-effect-resistant plans for targets with comparable dose distributions for normal tissues. A further study with a larger and more realistic patient population is warranted to generalize the conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.